Biocon Biologics is expanding its oncology portfolio with biosimilars for Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The move strengthens its cancer care offerings and global presence, following USFDA approval of Bevacizumab. Integration into Biocon Ltd. further enhances strategic growth, underscoring its mission to deliver affordable, innovative therapies worldwide.
Show moreStay Ahead – Explore Now! Deutsche Bank edges Jupiter target higher to 165p
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
